Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Uni Pharma's website does not show DR70 nor Onko Sure as a product. I think my guess was correct that UNI just paid the minimum amount to gain all the information on production of DR70 and did not pay the remaining $80,000.
After June 3, 2014, they can manufacture and sell Onko Sure when it loses patent protection.
http://www.uni-pharma.com/products/cpzsengliash.html#
If you look at Biocurex as an example, there offices were closed and assets foreclosed but they still have the same active phone number. Their website was also shut down and all that is left now is a phone message saying they can be contacted at biocurex@yahoo.com. Reverse look up has been blocked.
I would suspect Radient has done the same thing with their phone and it also may be a really inexpensive internet phone.
Old Git, the only area in the world where DR70 has had any market whatsoever is in southeast asia.
If you read the agreement with UNI, they paid $20,000 to have Radient transfer all of the manufacturing know how. That transfer was supposed to be complete with a full scale trial manufacturing by Radient for UNI. Upon completion of the trial manufacturing run, Radient was to get another $80,000 but no public information is available as to the proceedings of the manufacturing knowledge transfer.
We absolutely do know from the agreement that the agreement will be cancelled as of 6/3/2014 when the last issued patent expires.
After 4/3/2014, anyone who wishes to manufacture and sell DR70 is free to do so without any expectation of legal action from Radient.
After that date, there would be ABSOLUTELY ZERO reason for Radient to have any value at all in any type of corporate action.
Facts:
1. DR70 has never sold enough to even cover manufacturing costs.
2. The CIT patent is too old to be of any value since any possible development would exceed it's patent life.
3. The shell has no value because the millions in debt owed to the creditors would have to be resolved by any new owners of the shell.
4. Radient has no money to even declare bankruptcy.
5. The lack of up to date financial filings make any shell value decrease as time passes.
Anyone who thinks Radient has any value whatsoever just hasn't paid attention to the facts.
Old Git, you cannot "renew" patents. They have a finite life of 20 years from the effective date of application. Two patents concerning DR70 were issued. One has expired and the second expires in just over two months.
The agreement with UNI gave them the responsibility to continue the current patent application effort.
Even a rube falling off a turnip truck can see that it is not in the best interest of UNI to continue any patent application efforts. Just read the agreement.
1. Any royalty is no longer obligated after the last issued patent expires in June.
2. When the last issued patent expires, the agreement is cancelled. That is clearly stated in the agreement so there would be no obligation by UNI to continue any patent application efforts after June 2, 2014.
The last patent for DR70 expires 6/3/2014 per Radient SEC filings.
http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/img1.jpg
Radients last and only remaining patent for DR70 expires in 81 days. After that date, no one would have to pay any royalties for the manufacture of the product. That includes both UNI and Gartner. Both have gotten all of the manufacturing "know how" from Radient. They need nothing else. Gartner for $6,000 and UNI for $20,000.
"3.1.1 The total fee for UNI’s five year Onko-Sure DR-70 license is five hundred thousand dollars ($500,000) USD to be paid out annually as per Paragraph 1.2 in Exhibit B below. UNI shall pay up-front (the “Up-Front License Fee) one hundred thousand dollars ($100,000) to RXPC in two installments: twenty thousand USD ($20,000) will be wired upon co-signing of the License Agreement with the remaining eighty thousand ($80,000) to be wired to RXPC after tech transfer training and commercial-scale trial-run production for Onko-Sure (DR-70) from RXPC. This License Agreement will become effective upon receipt of the up-front license fee to RXPC."
From the above agreement, you could probably only assume that Radient has gotten the initial $20,000. Once the technology is transferred, you could also assume that UNI probably will not even pay the remaining $80,000. Also in the agreement, there are no royalty payments after the current remaining patent expires on June 3, 2014.
What can radient do if UNI does not pay the remaining $80,000? Do you really think any lawyer would take a case suing a Chinese company in Asia who has no assets in the USA?
Look carefully at the term and termination below. There is Zero motivation for UNI to continue any patent application. Radient will get no further money from UNI and the agreement will be cancelled June 3 of this year. UNI has the technology and know how and that is all they ever needed.
"Term and Termination
11.1 This Agreement shall become effective upon the date of signing by both Parties and continue in effect until the earlier to occur of: (i) expiration of the last patent issued to RXPC for the Licensed Products, (ii) when UNI terminates this Agreement by discontinuing the offering of the Licensed Products or the sublicense to do the same.
Yes, the PR phone number was the only one I ever posted was disconnected. The number for Radient was not disconnected but no one ever answers and the mailboxes are full.
Who knows the reason for leaving a phone connected. BioCurex is another company who closed their business but left their phone connected. Anyone who calls their number is directed to email a yahoo address.
For Radient, you cannot ever talk to anyone or leave any messages.
Lake, you made an interesting comment about the huge volume on Monday that is may have been used to pay the lawyers. There has to be some reason why the outstanding shares went to about 4.5 billion and the volume then dropped off. It could be that Mac signed the remaining shares over to the law firm. In any case, I think the OS has now definitely made it to 5 billion limit.
Lakeshore and Jimtash,
Radient is/was a Delaware corporation but no longer in "good standing"
California requires all corporations who actually operate within California to also be registered with the California division of corporation. That registration is also defunct.
It is clear that no money is being spent at all to ensure a corporate life for Radient and there is no reason whatsoever for anyone to buy or merge with Radient.
As for establishing a corporation with the corporation division of Nevada, the only reason people do that is because of very lax regulations. A big hint here. If you see a Nevada incorporated business and they are not actually in Nevada, watch out. You are likely dealing with a scam.
Dcspka, I had no posts removed nor did I even ask for any posts to be removed.
I did not post any information that MacLellan had resigned. I posted a link to the California Secretary of State which stated that the agent (an agent would be an officer or director for Radient) had resigned last year and as far as California goes, Radient is now a defunct corporation. All Radient had to do was continue submitting filings to the corporation division of the California Secretary of State as required by state law.
It is currently illegal for Radient to be conducting any business whatsoever in California.
Run coach, the wiki article stated that the agent for Radient resigned. However, it did say Mac was a former officer.
This is based on California filings so as far a California goes, Radient Pharmaceuticals no longer exists as a corporation.
IMO, Radient will just blow in the wind until the SEC finally acts to shut it down. In July of last year, the SEC shut down 62 pennies where the companies were no longer operating and people were attempting to manipulate the stock.
Business Search - Results
--------------------------------------------------------------------------------
Data is updated to the California Business Search on Wednesday and Saturday mornings. Results reflect work processed through Friday, February 14, 2014. Please refer to Processing Times for the received dates of filings currently being processed. The data provided is not a complete or certified record of an entity.
•Select an entity name below to view additional information. Results are listed alphabetically in ascending order by entity name.
•For information on checking or reserving a name, refer to Name Availability.
•For information on ordering certificates, copies of documents and/or status reports or to request a more extensive search, refer to Information Requests.
•For help with searching an entity name, refer to Search Tips.
•For descriptions of the various fields and status types, refer to Field Descriptions and Status Definitions.
Results of search for " RADIENT PHARMACEUTICALS " returned 1 entity record.
Entity Number Date Filed Status Entity Name Agent for Service of Process
C1824440 06/29/1992 FORFEITED RADIENT PHARMACEUTICALS CORPORATION ** RESIGNED ON 11/09/2012
This corporation is no longer active according to documents filed with California Secretary of State.
Douglas's past corporate interests include the President of Radient Pharmaceuticals Corporation Douglas has additional archived roles with one other company including:
• Past President of Radient Pharmaceuticals Corporation
Interesting, I missed the mention of BioCurex in the article. What I just noticed was the PAST TENSE in "was a director of BioCurex". There has never been an 8K saying Burger has resigned even though everyone is gone.
Moro has let the peptide patent expire for lack of a response. In any case, all the patents have been assigned to Centercourt and the other two funds run by Smithline. All of BioCurex's assets have been seized including all of the lab equipment. Their previous building is now a DNA testing company.
Burger attempted to put something together to keep Biocurex running about a year ago but was wanting Smithline to extend the debt. Smithline refused. Someone else attempted to take over the shell but wanted Smithline to take stock in a new company to cover his notes. Smithline refused. Smithline considers Moro to be a scam artist and is tired of hearing all the lies because nothing Moro ever told him was accurate. Smithline decided to shut Moro down and take everything even if it cost him money. That is how much Smithline disliked Moro.
Moro pocketed at least 1.7 million from Revenue Canada to compensate for R&D that had been paid for by BioCurex.
Prior to yesterday, this stock was selling for a penny. What happened was the news story about Paulson Capital and the old 2012 news of a loan from Paulson popped up on the BioCurex board. Some people must have thought that was recent news. Paulson gave Moro that money to pay off a death spiral note that was due. The money didn't even pay off the note. It was a total waste by Paulson. Moro was running a scam.
Dreher was only 60 when he left the company. I still think Mac forced him out. Also, in the filings, they never paid Dreher any of the severance due him.
IMO, they had just gotten DR70 FDA cleared and Jade was making money. I think Mac and his friends on the board wanted control.
Dreher was ousted by Mac in 2008 and it went rapidly downhill from there.
Also, did you notice that BioCurex was totally omitted from Burger's bio?.
All of the patents are owned by Centercourt as well as taking most of the lab equipment. They were seized on the loan default.
There are no assets left in Biocurex.
Only fools are buying this stock. Centercourt was offered stock in a new company who was interested in the shell but Smithline just wanted cash and be done with it. Smithline who runs Centercourt was totally fed up with the likes of Moro.
The shell is now getting stale and probably has little value at all.
Interesting article. Paulson was obviously not well run but I am totally shocked they appointed Burger back as a director. He is the dummy who threw all the money at BioCurex and lost it all.
On 03/14/11 03:18:38 PM I posted the following:
"When Jade blew up on them, that was the beginning of the end. Right now, the stock is being supported by misleading press releases and bloggers.
Note: The CEO made $750,000 in 2009. That's a pretty good motivation for keeping the stock alive."
It was true then as it is today. Instead of attempting to obtain some sort of product that might sell, Mac decided to hype DR70 with a name change and false PR's in order to continue to bleed the company for his own profit. He bled the company dry while he suckered lenders and investors alike to support a product he knew would never succeed.
All anyone needed to do was to research "universal cancer markers" to learn that the product would never be a success. There are many universal cancer markers that have been discovered and none have been successful. Three actually got funding and made a market attempt but most of them died after the research was published.
The biggest problem investors have with this stock is the fact that DR70 / Onko Sure will never have any material success in the market place.
Zero trades for RXPC for the past three days. Previous trades last week were all at less than the minimum quote of .0001.
It would appear that gamblers have decided to cease wasting their money.
No shares have sold since Friday. All of the sales on the 12th and 13th were at less than .0001.
$0.00
910
OTO
12/13
$0.00
40
OTO
12/13
$0.00
1,000,000
OTO
12/12
$0.00
60
OTO
12/12
$0.00
200
OTO
12/12
Maybe the small sales was someone who foolishly thought Radient somehow had value and hung onto the shares. Someone could have spread a merger rumor. Too bad he didn't sell earlier.
Expect to see a lot more of the .00 trades as the tax year closes out.
How to get rid of worthless stock for a tax loss.
"You generally need to sell shares to be able to write off the loss. But if the company goes completely out of business and there isn't anything left for shareholders, then you can deduct the loss as a worthless security without selling it.
But, as you've discovered, sometimes a company is in limbo -- with the shares still technically trading but nobody buying them. In that case, your broker may help take the shares off your hands so you can write off the loss.
Many brokers have special rules for buying nearly worthless stock from customers. E-Trade, for example, charges a $5 commission to buy shares in a worthless-securities liquidation, which provides you with a trade confirmation for your tax records.
Charles Schwab offers a courtesy sale for people who can't sell their shares. Schwab adjusts the commission to be the same amount as the sale price of the shares, so the net ends up being $0.
TD Ameritrade can purchase lots of shares for $1. Clients are charged the standard online commission of $9.99, minus the $1 received for the sale of the shares. If the client does not have enough cash in the account to cover the cost of the commission, TD Ameritrade will work with him or her to settle the trade. Clients cannot complete this transaction online and must call TD Ameritrade's toll-free number.
Read more at http://www.kiplinger.com/article/investing/T052-C001-S001-how-to-sell-worthless-stock.html#Meh3yuCfWAIarHxj.99
IMO, UNI paid the $20,000 when the manufacturing know how was transferred and I doubt there will be any further payments from UNI. If UNI does not pay, who is going to sue them? Radient cannot pay for a lawyer and no lawyer is going to work for Radient thinking they could get fees from a foreign company.
So Radient got 30k from UNI and 5K from Gartner for the transer of technology.
The WIPO does not issue or approve patent applications. When a patent if filed through the PCT system, the WIPO does a search to see if it can be patented and will make a list of appropriate references at the bottom of the search report. It is then the obligation of the inventor to then make actual patent applications with the appropriate patent offices of the countries where he wishes to have the patent application considered.
You would have to check the other offices to see if an application was filed and what has happened.
What I posted was the application for the European Union and it is no longer under consideration because fees were not paid.
India has there own patent office, Australia and many others.
The fact that the WIPO issued a search finding means nothing to an actual patent application other than establishing an effective date for the application.
For those who are counting on the patent, isn't it a bit concerning that the international patent application was abandoned?
Wasn't UNI supposed to be pursuing the patent applications? Doesn't that tell you that UNI doesn't care about the patent applications and will not be paying any royalties at all after they all expire or are abandoned?
UNI got the technology to manufacture and IMO, that was all they ever wanted. Same as Gartner.
Status Examination is in progress
Database last updated on 06.12.2013
Most recent event Tooltip 29.10.2013 New entry: Application deemed to be withdrawn: despatch of communication + time limit
Applicant(s) For all designated states
AMDL, Inc.
2492 Walnut Avenue, Suite 100
Tustin, CA 92780-6953 / US
[2012/06]
Inventor(s) 01 / SMALL-HOWARD, Andrea
12403 Jersey Avenue
Norwalk CA 90650 / US
[2012/06]
Representative(s) Potter Clarkson LLP
The Belgrave Centre, Talbot Street, Nottingham
NG1 5GG / GB
[2013/37]
Former [2012/06] Wright, Andrew John
Potter Clarkson LLP Park View House 58 The Ropewalk
Nottingham NG1 5DD / GB
Application number, filing date 09789550.2 30.03.2009
WO2009US38833
Priority number, date deleted
[2012/06]
Filing language EN
Procedural language EN
Publication Type : A1 Application with search report
No. : WO2010114514
Date : 07.10.2010
Language : EN
[2010/40]
Type : A1 Application with search report
No. : EP2414843
Date : 08.02.2012
Language : EN
The application has been published by WIPO in one of the EPO official languages on 07.10.2010
[2012/06]
International and Supplementary
search report(s) International search report -
published on: EP 07.10.2010
Classification International : G01N33/574, G01N33/86
[2012/06]
Designated contracting states AT , BE , BG , CH , CY , CZ , DE , DK , EE , ES , FI , FR , GB , GR , HR , HU , IE , IS , IT , LI , LT , LU , LV , MC , MK , MT , NL , NO , PL , PT , RO , SE , SI , SK , TR [2012/06]
Title German : NACHWEIS VON FIBRIN- UND FIBRINOGEN-ABBAUPRODUKTEN SOWIE DAMIT VERBUNDENE VERFAHREN ZUR HERSTELLUNG UND VERWENDUNG ZUM NACHWEIS UND ZUR ÜBERWACHUNG EINER KREBSERKRANKUNG [2012/06]
English : DETECTION OF FIBRIN AND FIBRINOGEN DEGRADATION PRODUCTS AND ASSOCIATED METHODS OF PRODUCTION AND USE FOR THE DETECTION AND MONITORING OF CANCER [2012/06]
French : DÉTECTION DE PRODUITS DE DÉGRADATION DE FIBRINE ET DE FIBRINOGÈNE, ET PROCÉDÉS CONNEXES DE PRODUCTION ET D'UTILISATION POUR LA DÉTECTION ET LA SURVEILLANCE D'UN CANCER [2012/06]
Entry into regional phase 18.10.2011 National basic fee paid
18.10.2011 Designation fee(s) paid
18.10.2011 Examination fee paid
Examination procedure 18.10.2011 Examination requested [2012/06]
18.05.2012 Amendment by applicant (claims and/or description)
10.09.2013 Despatch of a communication from the examining division (Time limit: M04)
30.10.2013 Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time
Divisional application(s) The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 10.09.2013
Fees paid Renewal fee
30.09.2011 Renewal fee patent year 03
26.03.2012 Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
31.03.2013 05 M06 Not yet paid
Cited in International search [I] US2004033544
[Y] WO9855872
[I] Anonymous: "GenWay Biotech/AMDL-ELISA DR-70 (FDP) test" online Internet article 2007, pages 1-4, XP002556535 Retrieved from the Internet: URL:http://www.genwaybio.com/images/gw_tds/elisa_kits/40-008-355001.pdf> [retrieved on 2009-11-19]
[X] LI X. ET AL.: "Serum concentration of AMDL DR-70 for the diagnosis and prognosis of carcinoma of the tongue" BR. J. ORAL & MAXILLOFAC. SURG., vol. 43, no. 6, December 2005 (2005-12), pages 513-515, XP002556536
DOI: http://dx.doi.org/10.1016/j.bjoms.2004.11.020
[X] KERBER A. ET AL.: "The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study" ALIMEN. PHARMACOL. & THER., vol. 20, no. 9, 1 November 2004 (2004-11-01), pages 983-987, XP002556537
DOI: http://dx.doi.org/10.1111/j.1365-2036.2004.02212.x
[X] WU D.F. ET AL.: "Sensitivity and specificity of DR-70(TM) lung cancer immunoassay" ANALYTICAL LETTERS, vol. 32, no. 7, May 1999 (1999-05), pages 1351-1362, XP009126042
DOI: http://dx.doi.org/10.1080/00032719908542902
[X] WU D. ET AL.: "Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection" J. IMMUNOASSAY, vol. 19, no. 1, February 1998 (1998-02), pages 63-72, XP009126130
[X] RUCKER P. ET AL.: "Elevated fibrinogen-fibrin degradation products (FDP) in serum of colorectal cancer patients" ANALYTICAL LETTERS, vol. 37, no. 14, November 2004 (2004-11), pages 2965-2976, XP009126041
DOI: http://dx.doi.org/10.1081/AL-200035849
[Y] MCCABE R.P. ET AL.: "A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin(ogen) degradation products" CANCER RES., vol. 44, no. 12 Part 1, December 1984 (1984-12), pages 5886-5893, XP009126033
[A] BICK R.L.: "The clinical significance of fibrinogen degradation products" SEMINARS IN THROMBOSIS AND HEMOSTASIS, vol. 8, no. 4, October 1982 (1982-10), pages 302-330, XP009126076
"Most recent event 29.10.2013 New entry: Application deemed to be withdrawn: despatch of communication + time limit "
That is the latest status as of Oct 29, 2013
https://register.epo.org/application?number=EP09789550
Lake, you are correct. The FDA will step in when something gets a lot of hype. The DNA tests could in fact harm people because if a gene indicated a possibility of breast cancer, ovarian cancer or some other malady, people were taking action. They were having healthy breasts removed, etc.
GenWay sold the test as a cancer screen, not just lab use. They had a website called "youtestyou.com"
They were selling it off label and I never saw any letter from the FDA shutting them down. What did happen was obvious though... They never sold many tests at all.
I doubt the FDA would shut Gartner down from selling DR70 tests. AMDL did indeed sell testing back in 2001 and GenWay had dr70 testing for sale from 2009 to 2012.
FDA action is based more on knee jerk reactions than anything else. They shut Lab Corp down from selling an ovarian cancer test kit because Lab Corp was selling a LOT of the tests. There is a law allowing home brew testing and that is what Gartner would be operating under. The Lab Corp test was a home brew but it used some software to analyze the results and the FDA mandated control of all software.
Lakeshore, the agreement with Gartner also transferred the technology to manufacture the test. Once Gartner had that and the patent expires, he could do as he wishes with DR70. Gartner still needs some fools money to get started.
Jimtash, there is one big difference between the 2011 and the 2013 UNI deals.
The 2013 deal transfers all the manufacturing knowhow and the rights to manufacture the test. Once that transfer of technology is done, Radient no longer needs to exist as a test manufacturer.
Also, in the agreement, UNI was supposedly be responsible for continuing all of the patent applications for the 2010 application. What would be the reason UNI allowed the WIP patent application to lapse for not paying fees?
Also, UNI only has to pay the 100k per year as long as patents or patent applications exist. The second patent for DR70 expires in April 2014 and if UNI also allows the US patent application to lapse, they would not need to pay any royalty at all.
Did you notice that Radient cannot even sue UNI if they don't comply with the contract?
Moro has abandoned the patent application for the peptide.
20120270238
11-06-2013 ABN Abandonment PROSECUTION